VAXCYTE, INC. Operating Lease Right-of-Use Assets
VAXCYTE, INC. (PCVX) had Operating Lease Right-of-Use Assets of $110.18 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-05
- 2026-06-30: Operating Lease, Right-of-Use Asset $110.18M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $113.10M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $116.01M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $83.52M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $110.18M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $113.10M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $116.01M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $83.52M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $85.65M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $87.76M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $72.10M 10-K · filed 2026-02-24 |
| 2024-09-30 | $28.70M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $26.78M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $28.91M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $31.00M 10-K · filed 2025-02-25 |
| 2023-09-30 | $16.33M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $18.01M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $19.66M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $21.29M 10-K · filed 2024-02-27 |
| 2022-09-30 | $22.89M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $24.56M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $26.12M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $27.96M 10-K · filed 2023-02-27 |
| 2021-09-30 | $307.00K 10-Q · filed 2022-11-07 |
| 2021-06-30 | $654.00K 10-Q · filed 2022-08-08 |
| 2021-03-31 | $1.03M 10-Q · filed 2021-05-11 |
| 2021-01-01 | $900.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |